ITCI:NGS-Intra-Cellular Therapies Inc. (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | Nasdaq Global Select

Last Closing

USD 73.26

Change

+1.13 (+1.57)%

Market Cap

USD 0.57B

Volume

0.59M

Analyst Target

USD 45.25
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is engaged in discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
NBIX Neurocrine Biosciences Inc

+0.64 (+0.46%)

USD 13.68B
VTRS Viatris Inc

-0.59 (-5.00%)

USD 13.36B
LNTH Lantheus Holdings Inc

+1.39 (+1.87%)

USD 4.49B
ALKS Alkermes Plc

+0.16 (+0.66%)

USD 4.11B
ALVO Alvotech

+0.06 (+0.44%)

USD 3.79B
HCM HUTCHMED DRC

+1.35 (+6.93%)

USD 3.23B
AVDL Avadel Pharmaceuticals PLC

-0.42 (-2.58%)

USD 2.99B
INDV Indivior PLC Ordinary Shares

+0.09 (+0.51%)

USD 2.93B
EVO Evotec SE ADR

+0.08 (+1.54%)

USD 2.51B
AMPH Amphastar P

+0.22 (+0.52%)

USD 2.06B

ETFs Containing ITCI

PSIL AdvisorShares Psychedelic.. 5.29 % 0.00 %

-0.01 (-0.54%)

USD 6.89M
IBRN iShares Trust - iShares N.. 4.82 % 0.00 %

-0.13 (-0.54%)

USD 3.84M
FBT:LSE First Trust Global Funds .. 3.44 % 0.00 %

-6.10 (-0.54%)

USD 6.57M
FBTU:LSE First Trust Global Funds .. 3.44 % 0.00 %

-0.06 (-0.54%)

USD 6.57M
BBP Virtus LifeSci Biotech Pr.. 0.00 % 0.79 %

+0.10 (+-0.54%)

USD 0.02B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

+1.08 (+-0.54%)

USD 1.08B
PILL Direxion Daily Pharmaceut.. 0.00 % 0.98 %

+0.02 (+-0.54%)

USD 0.01B
XPH SPDR® S&P Pharmaceutical.. 0.00 % 0.35 %

+0.02 (+-0.54%)

USD 0.20B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.29% 63% D 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.29% 63% D 62% D
Trailing 12 Months  
Capital Gain 17.88% 71% C- 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.88% 71% C- 73% C
Trailing 5 Years  
Capital Gain 436.70% 98% N/A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 436.70% 98% N/A 96% N/A
Average Annual (5 Year Horizon)  
Capital Gain 54.51% 87% B+ 91% A-
Dividend Return 54.51% 87% B+ 91% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 51.62% 48% F 32% F
Risk Adjusted Return 105.59% 100% F 98% N/A
Market Capitalization 0.57B 97% N/A 90% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 11.30 11% 10%
Price / Cash Flow Ratio -53.80 96% 94%
Price/Free Cash Flow Ratio -39.03 96% 94%
Management Effectiveness  
Return on Equity -22.39% 57% 43%
Return on Invested Capital -25.65% 44% 32%
Return on Assets -13.43% 41% 30%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.